Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ten-eleven translocation 1 (TET1) is a dioxygenase enzyme encoded by the TET1 gene that catalyzes the sequential oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) in an Fe(II)/α-ketoglutarate-dependent manner, facilitating active DNA demethylation and chromatin regulation.[1][2][5][9] It contains a CXXC domain for binding unmethylated CpG sites and a catalytic domain with cysteine-rich and double-stranded β-helix regions.[1] TET1 recruits histone-modifying complexes to influence gene activation/repression and plays roles in embryonic stem cell maintenance, macrophage differentiation, proinflammatory responses, and processes like liver regeneration and iron homeostasis.[1][2][3] Expressed highly in embryonic stem cells and primordial germ cells, it was first identified as an MLL fusion partner in acute myeloid leukemia.[1][5] Isoforms differ in chromatin affinity and replication site localization.[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ten-eleven translocation 1 (TET1) (TET1).